en · de · es
ipamorelin-notes.peptides1126.com › News › Receptor Mechanism And Secretagogue Action — Complete Guide

Receptor Mechanism And Secretagogue Action — Complete Guide

By Editorial Desk · published 2026-03-05 · last reviewed 2026-03-30 · News

A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Background and Structural Identity

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Ipamorelin at a glance

PropertyValueNotes
Molecular classSynthetic pentapeptideChain of five amino acid residues
Molecular massApproximately 712 DaConsistent with a five-residue chain
Receptor targetGHS-R1aGrowth hormone secretagogue receptor
Primary actionGrowth hormone releasePituitary somatotroph stimulation
Research originDeveloped in the 1990sSmall-peptide secretagogue program

背景与受体作用机制

现有文献多来自小规模、短期的研究,涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏,以及重复给药后效应是否衰减,仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大,因此结论外推需谨慎。关于临床获益的确切证据尚不充分,需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Related pages on this site

Receptor Selectivity and Secretagogue Signaling

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Handling, Storage, and Analytical Characterization

Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.

Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.

Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.

Supporting material

Wiechelman, K.; Braun, R. & Fitzpatrick, J. (1988). "Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation". Anal. Biochem. 175 (1): 231–7. doi:10.1016/0003-2697(88)90383-1. PMID 3245570. Stoscheck, CM. (1990). "6". Quantitation of Protein. Methods in Enzymology. Vol. 182. pp. 50–69. doi:10.1016/0076-6879(90)82008-P. ISBN 9780121820831. PMID 2314256.

=== Biomedical === Nanoscale particles are used in biomedical applications as drug carriers or imaging contrast agents in microscopy. Anisotropic nanoparticles are a good candidate in biomolecular detection. Moreover, nanoparticles for nucleic acid delivery offer an unprecedented opportunity to overcome some drawbacks related to the delivery, owing to their tunability with diverse physico-chemical properties, they can readily be functionalized with any type of biomolecules/moieties for selective targeting. Using nanoparticles in cancer treatment is being extensively researched. Certain characteristics of the tumor microenvironment, including leaky vasculature and poor lymphatic drainage, lead to the accumulation of NPs in the tumor. This is known as the enhanced permeability and retention (EPR) effect, and is a type of passive targeting. Additionally, ligands that bind to certain expressed or over-expressed receptors in the tumor microenvironment can be conjugated to the surface of nanoparticles to actively target the tumor. The accumulation of nanoparticles in the tumor can reduce adverse side effects, which is a major drawback of chemotherapy. In drug delivery, the acidic pH of the tumor microenvironment is often exploited to increase the release of the drug from pH-sensitive materials. Additionally, some NPs can generate heat under laser irradiation (photothermal therapy) or alternating magnetic field (magnetic hyperthermia), which can both kill cancer cells, and release drugs loaded in the nanoparticle.

=== COVID-19 pandemic === During the COVID-19 pandemic in Missouri, Schmitt filed lawsuits to prevent St. Louis County from implementing public health restrictions (such as restrictions on indoor dining, mask mandates and limits on gatherings) to reduce COVID-19's spread. He opposed the release from jail of some inmates charged with violent felonies during the pandemic, a measure that had been proposed to reduce COVID-19 spread in detention facilities. Schmitt was involved in efforts to combat scammers and price gougers attempting to profiteer from COVID-19. In March 2020, he sued televangelist Jim Bakker and Morningside Church Productions, Inc. for falsely claiming that "Silver Solution" (colloidal silver) was an effective COVID-19 treatment. In April 2020, on behalf of the State of Missouri, Schmitt sued the Chinese government, Chinese Communist Party, and other Chinese officials and institutions in the U.S. District Court for the Eastern District of Missouri, alleging that their actions to suppress information, arrest whistleblowers, and deny COVID-19's contagious nature led to loss of life and severe economic consequences in Missouri. Missouri is the first state to sue China over the pandemic. Schmitt described the lawsuit as a historic accountability measure, but legal experts called it a public relations stunt. The nine defendants were not served for more than a year after the complaint's filing, and the state spent $12,000 to translate the complaint into Chinese. In July 2022, U.S. District Judge Stephen N. Limbaugh Jr.

Candelariella deppeanae is a species of lichen in the family Candelariaceae. Found in southwestern North America, it was formally described as a new species in 2007 by the Swedish lichenologist Martin Westberg. The type specimen was collected in the Chiricahua Mountains (Chiricahua National Monument, Arizona) at an elevation of 1,750 m (5,740 ft). Here, in an oak forest, it was found growing on a decorticated (barkless) part of alligator juniper (Juniperus deppeana). Most collections of the lichen are from the wood or trunks of this juniper plant; the species epithet deppeanae alludes to this close relationship. The lichen has a greenish-yellow to yellow, granular to areolate thallus. It has also been collected in Texas, and from Chihuahua, Baja California Norte and Baja California Sur. The lichen grows mainly on wood and decorticated trunks, but has also been less frequently recorded growing on bark. Secondary chemicals that have been detected in Candelariella deppeanae (using high-performance liquid chromatography) include calycin, pulvic acid lactone, vulpinic acid, and pulvinic acid.

=== Glutaminolysis and transamination === Aside from the citric acid cycle, α-ketoglutarate is made by glutaminolysis in which the enzyme glutaminase removes the amino group from glutamine to form glutamate which is converted to α-ketoglutarate by any one of three enzymes, glutamate dehydrogenase, alanine transaminase, or aspartate transaminase (see The glutaminolytic pathways). It is also made through the action of pyridoxal phosphate-dependent enzymes (alanine transaminase) in which glutamate is converted to α-Ketoglutarate by "donating" its −NH2 to other compounds (see transamination). These reactions are reversible. In the reverse direction of these reactions, α-ketoglutarate contributes to the production of amino acids such as glutamine, proline, arginine, and lysine as well as the lowering of cellular carbon and nitrogen (i.e., N) levels; this prevents excessive levels of these two potentially toxic elements from accumulating in cells and tissues. The neurotoxin, ammonia (i.e., NH3), is also prevented from accumulating in tissues. In this metabolic pathway the −NH2 group on an amino acid is transferred to α-ketoglutarate; this forms the α-keto acid of the original amino acid and the amine-containing product of α-ketoglutarate, glutamate. The cellular glutamate passes into the circulation and is taken up by the liver where it delivers its acquired −NH2 group to the urea cycle. In effect, the latter pathway removes excess ammonia from the body in the form of urinary urea.

Sources: en.wikipedia.org

Notes from published material

=== Domestic pressures in the US === Some critics have described the United States intervention against Iran as a diversionary war, noting mounting domestic pressures including intense public scrutiny following the publication of the Epstein files, Operation Metro Surge by ICE, and the economic impact of global tariffs which have contributed to falling approval ratings and legal actions. Representative Thomas Massie and former Representative Marjorie Taylor Greene argued Trump started the war as a distraction from the Epstein files.

The New Union Treaty (Russian: Новый союзный договор, romanized: Novyy soyuznyy dogovor) was a 1990 draft treaty that would have replaced the 1922 Treaty on the Creation of the Union of Soviet Socialist Republics (USSR) to salvage and reform the USSR. The preparation of this treaty was known as the Novo-Ogaryovo process, named after Novo-Ogaryovo, a governmental estate where the work on the document was carried out and where Soviet President and CPSU General Secretary Mikhail Gorbachev talked with leaders of Union republics. A ceremony of the Russian SFSR signing the treaty was scheduled for 20 August 1991, but was prevented by the August Coup. In its aftermath, the Soviet Union ultimately dissolved by December of the same year, and the Commonwealth of Independent States was set up in its place.

The genetic loss of MECP2 has been identified as changing the properties of cells in the locus ceruleus, the exclusive source of noradrenergic innervation to the cerebral cortex and hippocampus. Researchers have concluded that "Because these neurons are a pivotal source of norepinephrine throughout the brainstem and forebrain and are involved in the regulation of diverse functions disrupted in Rett syndrome, such as respiration and cognition, we hypothesize that the locus ceruleus is a critical site at which loss of MECP2 results in CNS dysfunction."

An organic compound is a chemical whose molecules contain carbon. Carbon is abundant in the Sun, stars, comets, and in the atmospheres of most planets of the Solar System. Organic compounds are relatively common in space, formed by "factories of complex molecular synthesis" which occur in molecular clouds and circumstellar envelopes, and chemically evolve after reactions are initiated mostly by ionizing radiation. Purine and pyrimidine nucleobases including guanine, adenine, cytosine, uracil, and thymine, as well as sugars, have been found in meteorites. These could have provided the materials for DNA and RNA to form on the early Earth. The amino acid glycine was found in material ejected from comet Wild 2; it had earlier been detected in meteorites. Comets are encrusted with dark material, thought to be a tar-like organic substance formed from simple carbon compounds under ionizing radiation. A rain of material from comets could have brought such complex organic molecules to Earth. During the Late Heavy Bombardment, meteorites may have delivered up to five million tons of organic prebiotic elements to Earth per year. Currently 40,000 tons of cosmic dust falls to Earth each year.

In molecular biology, Enhancer of rudimentary homolog is a protein that in humans is encoded by the ERH gene. The Drosophila protein enhancer of rudimentary protein is a small protein of 104 amino acids. It has been found to be an enhancer of the rudimentary gene, involved in pyrimidine biosynthesis. From an evolutionary point of view, enhancer of rudimentary is highly conserved and has been found to exist in probably all multicellular eukaryotic organisms. It has been proposed that this protein plays a role in the cell cycle. PDBe-KB provides an overview of all the structure information available in the PDB for Human Enhancer of rudimentary homolog (ERH) PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Enhancer of rudimentary homolog (ERH)

Sources: en.wikipedia.org

Frequently asked questions

What receptor does ipamorelin act on?

It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.

How does ipamorelin differ from earlier secretagogues?

In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.

Is the mechanism of action fully understood?

The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Network